European Innovation Council

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Founded in 2016, SAALG Geomechanics specializes in real-time ground analysis software for civil works and building projects. It offers machine learning-driven solutions to anticipate ground movement issues, along with numerical models calibrations, soil parameter characterization, and geotechnical consulting services.

Founded in 2016, SAALG Geomechanics specializes in real-time ground analysis software for civil works and building projects. It offers machine learning-driven solutions to anticipate ground movement issues, along with numerical models calibrations, soil parameter characterization, and geotechnical consulting services.

Aortyx is a pioneering company founded by researchers from IQS School of Engineering and Hospital Clínic de Barcelona. It specializes in developing endovascular devices designed to treat aortic diseases, focusing on tissue regeneration through mimicking the aorta's biomechanical environment.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

X1 Wind is a company based in Barcelona, Spain, specializing in the development of innovative floating wind platforms for deep-water offshore wind energy. Founded in 2017, X1 Wind has engineered its platform to achieve a significant reduction in both cost and weight—by 50 percent and 80 percent, respectively—compared to traditional floating wind systems. The design features fewer active systems than current alternatives, allowing for simplified installation that can be completed at the port and transported to the site using a small tugboat. This approach not only enhances operational depth range but also improves scalability and reduces maintenance requirements. By focusing on these advancements, X1 Wind aims to provide a clean, affordable energy solution while contributing to global efforts to lower carbon emissions.

Unblur is a technology company based in Barcelona, Spain, founded in 2015. It specializes in developing AI software tailored for public emergency services, including firefighters, civil protection, and police. Unblur's primary offering is the IRIS platform, a modular Software as a Service (SaaS) solution designed to enhance real-time situational awareness during incidents. The platform centralizes all relevant data and tools, enabling incident commanders to coordinate teams effectively and make informed decisions, ultimately improving operational response in emergency situations.

Unblur is a technology company based in Barcelona, Spain, founded in 2015. It specializes in developing AI software tailored for public emergency services, including firefighters, civil protection, and police. Unblur's primary offering is the IRIS platform, a modular Software as a Service (SaaS) solution designed to enhance real-time situational awareness during incidents. The platform centralizes all relevant data and tools, enabling incident commanders to coordinate teams effectively and make informed decisions, ultimately improving operational response in emergency situations.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

AEInnova develops autonomous industrial monitoring devices for predictive maintenance. Its flagship device InduEye is battery-free, self-powered, and capable of edge computing for real-time vibration, thermal, and steam-trap monitoring, powered by waste heat with optional solar or wind energy. It uses LoRaWAN or NB-IoT/LTE-CAT M for communications and streams data to cloud dashboards with analytics, alarms, and environmental impact analysis. The system aims to reduce downtime and maintenance costs through non-invasive, self-sustaining monitoring. Certifications include CE and ATEX/IECEX, with FCC ongoing. The technology is deployed across sectors such as oil and gas, aluminium, steel, paper, rubber, water treatment, and energy, with customers including Repsol, Cepsa, ArcelorMittal, Enel, and others. AEInnova has been recognized as a leading EU scale-up with multiple awards and EC funding, and participates in EU R&D initiatives related to energy harvesting and high-temperature IoT.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

AEInnova develops autonomous industrial monitoring devices for predictive maintenance. Its flagship device InduEye is battery-free, self-powered, and capable of edge computing for real-time vibration, thermal, and steam-trap monitoring, powered by waste heat with optional solar or wind energy. It uses LoRaWAN or NB-IoT/LTE-CAT M for communications and streams data to cloud dashboards with analytics, alarms, and environmental impact analysis. The system aims to reduce downtime and maintenance costs through non-invasive, self-sustaining monitoring. Certifications include CE and ATEX/IECEX, with FCC ongoing. The technology is deployed across sectors such as oil and gas, aluminium, steel, paper, rubber, water treatment, and energy, with customers including Repsol, Cepsa, ArcelorMittal, Enel, and others. AEInnova has been recognized as a leading EU scale-up with multiple awards and EC funding, and participates in EU R&D initiatives related to energy harvesting and high-temperature IoT.

AEInnova develops autonomous industrial monitoring devices for predictive maintenance. Its flagship device InduEye is battery-free, self-powered, and capable of edge computing for real-time vibration, thermal, and steam-trap monitoring, powered by waste heat with optional solar or wind energy. It uses LoRaWAN or NB-IoT/LTE-CAT M for communications and streams data to cloud dashboards with analytics, alarms, and environmental impact analysis. The system aims to reduce downtime and maintenance costs through non-invasive, self-sustaining monitoring. Certifications include CE and ATEX/IECEX, with FCC ongoing. The technology is deployed across sectors such as oil and gas, aluminium, steel, paper, rubber, water treatment, and energy, with customers including Repsol, Cepsa, ArcelorMittal, Enel, and others. AEInnova has been recognized as a leading EU scale-up with multiple awards and EC funding, and participates in EU R&D initiatives related to energy harvesting and high-temperature IoT.

X1 Wind is a company based in Barcelona, Spain, specializing in the development of innovative floating wind platforms for deep-water offshore wind energy. Founded in 2017, X1 Wind has engineered its platform to achieve a significant reduction in both cost and weight—by 50 percent and 80 percent, respectively—compared to traditional floating wind systems. The design features fewer active systems than current alternatives, allowing for simplified installation that can be completed at the port and transported to the site using a small tugboat. This approach not only enhances operational depth range but also improves scalability and reduces maintenance requirements. By focusing on these advancements, X1 Wind aims to provide a clean, affordable energy solution while contributing to global efforts to lower carbon emissions.